MEP43208A - Epitopna vakcina beta-amiloidne-analogne-t-ćelije - Google Patents

Epitopna vakcina beta-amiloidne-analogne-t-ćelije

Info

Publication number: MEP43208A
Authority: ME; Montenegro
Prior art keywords: amyloid; methods; app; analogs; vaccination
Prior art date: 2001-08-20

Application number

MEP-432/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Peter Birk Rasmussen

Martin Roland Jensen

Klaus Gregorius Nielsen

Peter Koefoed

Florence Dal Degan

Original Assignee

Pharmexa As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-20

Filing date

2002-08-20

Publication date

2011-02-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP43208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-20 Application filed by Pharmexa As filed Critical Pharmexa As

2011-02-10 Publication of MEP43208A publication Critical patent/MEP43208A/xx

Links

229960005486 vaccine Drugs 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 5
101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
238000002255 vaccination Methods 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
238000002649 immunization Methods 0.000 abstract 2
230000003053 immunization Effects 0.000 abstract 2
150000007523 nucleic acids Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
230000007082 Aβ accumulation Effects 0.000 abstract 1
230000003942 amyloidogenic effect Effects 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Microbiology (AREA)
Zoology (AREA)
Environmental Sciences (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Psychology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Obesity (AREA)

MEP-432/08A 2001-08-20 2002-08-20 Epitopna vakcina beta-amiloidne-analogne-t-ćelije MEP43208A (bs)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
DKPA200101231		2001-08-20
US33754301P	2001-10-22	2001-10-22
US37302702P	2002-04-16	2002-04-16
DKPA200200558		2002-04-16
YU13304A RS51699B (sr)	2001-08-20	2002-08-20	Beta-amiloid-analog-t-ćelijski-epitop vakcina
PCT/DK2002/000547 WO2003015812A2 (en)	2001-08-20	2002-08-20	Beta-amyloid-analogue-t-cell epitop vaccine

Publications (1)

Publication Number	Publication Date
MEP43208A true MEP43208A (bs)	2011-02-10

Family

ID=32870659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-432/08A MEP43208A (bs)	2001-08-20	2002-08-20	Epitopna vakcina beta-amiloidne-analogne-t-ćelije

Country Status (29)

Country	Link
US (3)	US20030157117A1 (sr)
EP (3)	EP1685847A1 (sr)
JP (2)	JP2004538332A (sr)
KR (3)	KR20100086520A (sr)
CN (1)	CN101675992B (sr)
AR (1)	AR036270A1 (sr)
AT (1)	ATE334698T1 (sr)
AU (3)	AU2002325199B2 (sr)
BR (1)	BR0212047A (sr)
CA (1)	CA2457140C (sr)
CO (1)	CO5560581A2 (sr)
CY (1)	CY1105737T1 (sr)
DE (1)	DE60213615T3 (sr)
DK (1)	DK1420815T3 (sr)
EA (2)	EA007533B1 (sr)
ES (1)	ES2269749T5 (sr)
HR (2)	HRP20040218A2 (sr)
HU (1)	HUP0400669A3 (sr)
IL (2)	IL159964A0 (sr)
IS (1)	IS7133A (sr)
ME (1)	MEP43208A (sr)
MX (1)	MXPA04001467A (sr)
MY (1)	MY144532A (sr)
NZ (2)	NZ547224A (sr)
PL (1)	PL215125B1 (sr)
PT (1)	PT1420815E (sr)
RS (1)	RS51699B (sr)
SI (1)	SI1420815T1 (sr)
WO (1)	WO2003015812A2 (sr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ20022748A3 (cs) *	2000-02-21	2004-03-17	Pharmexa A/S	Nová metoda regulace obsahu amyloidu
ES2248283T3 (es) *	2000-02-21	2006-03-16	Pharmexa A/S	Nuevo procedimiento para reducir los niveles de amiloide.
US7264810B2 (en)	2001-01-19	2007-09-04	Cytos Biotechnology Ag	Molecular antigen array
MY144532A (en) *	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
US8506959B2 (en) *	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) *	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) *	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) *	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US9034337B2 (en) *	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
KR100546066B1 (ko) *	2003-03-21	2006-01-26	한국생명공학연구원	베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005042575A2 (en) *	2003-10-30	2005-05-12	Pharmexa A/S	Method for down-regulation of vegf
WO2005047860A2 (en)	2003-11-08	2005-05-26	Elan Pharmaceuticals, Inc.	Antibodies to alpha-synuclein
EP1711208A2 (en) *	2004-01-28	2006-10-18	Curix APS	Conjugates of amyloid proteins as vaccines for amyloid-related diseases
KR100639397B1 (ko) *	2004-03-18	2006-10-26	(주)에스제이바이오메드	항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
GB0424563D0 (en) *	2004-11-05	2004-12-08	Novartis Ag	Organic compounds
NZ562434A (en) *	2005-05-05	2010-04-30	Merck & Co Inc	Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
RU2432362C2 (ru)	2005-11-30	2011-10-27	Эбботт Лэборетриз	Моноклональные антитела и их применения
PL2289909T3 (pl)	2005-11-30	2015-04-30	Abbvie Inc	Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
EP1992639A4 (en) *	2006-02-22	2009-08-26	Hayashibara Biochem Lab	PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AN ANTIAMYLOID PEPTIDANT BODY
US8188046B2 (en)	2006-10-16	2012-05-29	University Of South Florida	Amyloid beta peptides and methods of use
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8147833B2 (en) *	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) *	2007-02-23	2015-11-30	Prothena Biosciences Ltd	Zapobieganie i leczenie synukleinopatii i amyloidozy
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
US7618944B2 (en)	2007-03-01	2009-11-17	Intezyne Technologies, Inc.	Encapsulated amyloid-beta peptides
WO2008124646A2 (en) *	2007-04-06	2008-10-16	The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services	Use of amyloid proteins as vaccine scaffolds
EP2149584B1 (en)	2007-04-20	2017-12-13	The Chemo-Sero-Therapeutic Research Institute	Method for enhancing immune response with peptide
AU2009268808A1 (en) *	2008-07-08	2010-01-14	Merck Sharp & Dohme Corp.	Vaccine for the treatment of Alzheimer's disease
JP5474807B2 (ja) *	2008-10-16	2014-04-16	一般財団法人化学及血清療法研究所	改変アミロイドβペプチド
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
EP3527220A1 (en)	2010-08-12	2019-08-21	AC Immune S.A.	Vaccine engineering
CN103298833B (zh)	2010-08-14	2015-12-16	Abbvie公司	β淀粉样蛋白结合蛋白
AR083561A1 (es)	2010-10-26	2013-03-06	Ac Immune Sa	Preparacion de una construccion antigenica
US20120321694A1 (en) *	2010-10-27	2012-12-20	Daniel Larocque	Compositions and uses
CA2885924C (en)	2012-08-21	2022-12-13	Institute For Molecular Medicine, Inc.	Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
EP3027205A4 (en)	2013-07-28	2017-07-19	Qantu Therapeutics, Inc.	Vaccine formulations that induce a th2 immune response
CN106163540A (zh) *	2013-09-13	2016-11-23	安达卢西亚进步与健康公共基金会	用于治疗蛋白病或构象病的聚集蛋白和分子伴侣的组合
CA2941416C (en) *	2014-03-11	2022-10-18	Universite D'aix-Marseille	A chimeric peptide that interacts with cell membrane gangliosides
US10441649B2 (en) *	2015-02-02	2019-10-15	The University Of Birmingham	Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
CN104880441B (zh) *	2015-05-14	2017-12-22	上海皓拓生物技术有限公司	β‑分泌酶特异性抑制剂的筛选方法及其筛选系统
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
RU2019109039A (ru)	2016-10-28	2020-11-30	Х. Лундбекк А/С	Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов, предназначенные для лечения психических и/или когнитивных расстройств
MX2019004859A (es)	2016-10-28	2019-06-20	H Lundbeck As	Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
WO2018132768A1 (en) *	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
CN108187038B (zh) *	2017-05-25	2020-05-01	成都安特金生物技术有限公司	一种狂犬病结合疫苗
MX2020006174A (es)	2017-12-14	2022-09-27	H Lundbeck As	Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas.
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en)	2017-12-20	2019-06-27	H. Lundbeck A/S	Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
EP3773712A1 (en) *	2018-04-10	2021-02-17	AC Immune SA	Anti-abeta therapeutic vaccines
CN112165956A (zh) *	2018-04-10	2021-01-01	Ac免疫有限公司	抗Aβ治疗性疫苗
US12605463B2 (en)	2019-04-12	2026-04-21	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
EP3952913A4 (en) *	2019-04-12	2023-05-10	The Johns Hopkins University	Tolerogenic artificial antigen-presenting cells
GB202008250D0 (en) *	2020-06-02	2020-07-15	Emergex Vaccines Holding Ltd	Diagnosis, prevention and treatment of coronavirus infection
CN117222664A (zh) *	2021-01-29	2023-12-12	拜耳动物保健有限责任公司	用于破坏自身耐受的疫苗组合物
CN115925987A (zh) *	2022-02-28	2023-04-07	安域生物科技(杭州)有限公司	基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN117700525B (zh) *	2024-02-05	2024-06-18	上海良润生物医药科技有限公司	一种多肽改造体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA811368B (en)	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en)	1981-09-04	1986-06-24	The Regents Of The University Of California	Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja)	1982-08-30	1984-03-02	Musashi Eng Kk	紙葉判別方法
US4599231A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en)	1984-03-09	1986-07-08	Scripps Clinic And Research Foundation	Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en)	1984-11-09	1986-08-26	Pitman-Moore, Inc.	LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en)	1985-05-01	1986-07-22	The United States Of America As Represented By The Department Of Health And Human Services	Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5223482A (en)	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5278056A (en)	1988-02-05	1994-01-11	The Trustees Of Columbia University In The City Of New York	Retroviral packaging cell lines and process of using same
US5192688A (en)	1988-08-15	1993-03-09	Switzer Iii Robert C	Histological analysis method
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US5200339A (en)	1990-08-17	1993-04-06	Abraham Carmela R	Proteases causing abnormal degradation of amyloid β-protein precursor
US5780587A (en)	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5780036A (en)	1991-08-26	1998-07-14	The Scripps Research Institute	Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
AU685047B2 (en)	1992-02-11	1998-01-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Dual carrier immunogenic construct
WO1993020220A1 (en)	1992-03-27	1993-10-14	Whitehead Institute For Biomedical Research	Non-infectious hiv particles and uses therefor
US5851787A (en)	1992-04-20	1998-12-22	The General Hospital Corporation	Nucleic acid encoding amyloid precursor-like protein and uses thereof
WO1993023076A1 (en)	1992-05-20	1993-11-25	The Johns-Hopkins University	Alternative receptor therapy
DK100592D0 (da)	1992-08-10	1992-08-10	Mouritsen & Elsner Aps	Metode til kemisk kobling paa faste faser
US5958883A (en) *	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
US5747323A (en)	1992-12-31	1998-05-05	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Retroviral vectors comprising a VL30-derived psi region
AU707083B2 (en)	1993-08-26	1999-07-01	Bavarian Nordic Inc.	Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK96493D0 (da)	1993-08-26	1993-08-26	Mouritsen Og Elsner Aps	Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU698962B2 (en) *	1993-09-14	1998-11-12	Epimmune, Inc.	Alteration of immune response using pan DR-binding peptides
AUPM411994A0 (en)	1994-02-25	1994-03-24	Deakin Research Limited	Epitopes
US5709995A (en)	1994-03-17	1998-01-20	The Scripps Research Institute	Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5573916A (en)	1994-05-19	1996-11-12	Coretech, Inc.	Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
IL115743A0 (en)	1994-10-28	1996-01-19	American Nat Red Cross	A mammal with cells containing a transgene and its production
US5589154A (en) *	1994-11-22	1996-12-31	Rutgers, The State University Of New Jersey	Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
EP0815134B1 (en)	1995-03-14	2002-06-05	Praecis Pharmaceuticals Incorporated	Modulators of amyloid aggregation
ATE339436T1 (de)	1995-06-07	2006-10-15	Sanofi Pasteur Inc	Expression von lipoproteinen
US5874469A (en)	1996-01-05	1999-02-23	Alcon Laboratories, Inc.	Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5985581A (en)	1996-07-25	1999-11-16	The Mclean Hospital Corporation	Use of presenilin-1 for diagnosis of alzheimers disease
AUPO390396A0 (en)	1996-11-29	1996-12-19	Csl Limited	Novel promiscuous T helper cell epitopes
EP1005374B1 (en)	1997-01-22	2007-04-18	Zycos Inc.	Microparticles for delivery of nucleic acid
WO1999024468A1 (en)	1997-11-11	1999-05-20	The Board Of Regents Of The University Of Oklahoma	An alzheimer-related, endothelium-derived toxic factor and methods for its use
US6761888B1 (en) *	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6913745B1 (en) *	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) *	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20040062802A1 (en)	1998-04-02	2004-04-01	Hermelin Victor M.	Maximizing effectiveness of substances used to improve health and well being
NO314086B1 (no) *	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
NZ509917A (en)	1998-07-21	2003-05-30	Pharmexa As	Coating of solid surfaces with activated polyhydroxypolymers
CN1318105A (zh)	1998-09-15	2001-10-17	M&E生物技术公司	负调节Osteoprotegerin配体活性的方法
IL141868A0 (en) *	1998-10-05	2002-03-10	M & E Biotech As	Novel methods for therapeutic vaccination
US6403537B1 (en) †	1998-11-06	2002-06-11	Baker Hughes Incorporated	Drilling fluid systems with improved fluid loss properties
AU2495300A (en)	1999-01-07	2000-07-24	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Lentivirus vector system
DE60014076T2 (de)	1999-04-19	2005-10-13	Glaxosmithkline Biologicals S.A.	Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6787637B1 (en) *	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
AR024558A1 (es)	1999-06-01	2002-10-16	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
NZ540564A (en)	1999-11-29	2007-04-27	Neurochem Int Ltd	Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
ES2275570T3 (es) *	1999-12-08	2007-06-16	Intellect Neurosciences, Inc.	Peptidos amiloides beta quimericos.
CZ20022748A3 (cs)	2000-02-21	2004-03-17	Pharmexa A/S	Nová metoda regulace obsahu amyloidu
ES2248283T3 (es) *	2000-02-21	2006-03-16	Pharmexa A/S	Nuevo procedimiento para reducir los niveles de amiloide.
GB0004530D0 (en)	2000-02-25	2000-04-19	Univ Nottingham	Adjuvants
US6713450B2 (en) *	2000-05-22	2004-03-30	New York University	Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits
HUP0600589A2 (en)	2000-11-10	2006-11-28	Wyeth Corp	Adjuvant combination formulations
US7097837B2 (en)	2001-02-19	2006-08-29	Pharmexa A/S	Synthetic vaccine agents
JP2002273199A (ja) *	2001-03-15	2002-09-24	Idemitsu Petrochem Co Ltd	ガス状流体の抜き出し方法
US6906169B2 (en)	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
US20030185845A1 (en)	2001-11-16	2003-10-02	Steen Klysner	Novel immunogenic mimetics of multimer proteins
AU2003203140A1 (en)	2002-01-17	2003-07-30	Pharmexa A/S	Immunogenic carcinoembryonic antigen (cea)
AU2003208314A1 (en)	2002-03-11	2003-09-22	Pharmexa A/S	Novel application of vaccination against tnf-alpha
WO2004006861A2 (en)	2002-07-17	2004-01-22	Mindset Biopharmaceuticals Usa Inc.	Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease

2002
- 2002-08-13 MY MYPI20023002A patent/MY144532A/en unknown
- 2002-08-20 CA CA2457140A patent/CA2457140C/en not_active Expired - Fee Related
- 2002-08-20 HR HR20040218A patent/HRP20040218A2/hr not_active Application Discontinuation
- 2002-08-20 WO PCT/DK2002/000547 patent/WO2003015812A2/en not_active Ceased
- 2002-08-20 BR BR0212047-0A patent/BR0212047A/pt not_active IP Right Cessation
- 2002-08-20 ES ES02758181.8T patent/ES2269749T5/es not_active Expired - Lifetime
- 2002-08-20 US US10/223,809 patent/US20030157117A1/en not_active Abandoned
- 2002-08-20 DK DK02758181T patent/DK1420815T3/da active
- 2002-08-20 KR KR1020107015762A patent/KR20100086520A/ko not_active Ceased
- 2002-08-20 KR KR10-2004-7002557A patent/KR20040044465A/ko not_active Ceased
- 2002-08-20 ME MEP-432/08A patent/MEP43208A/xx unknown
- 2002-08-20 HU HU0400669A patent/HUP0400669A3/hu not_active Application Discontinuation
- 2002-08-20 SI SI200230418T patent/SI1420815T1/sl unknown
- 2002-08-20 EP EP06000288A patent/EP1685847A1/en not_active Ceased
- 2002-08-20 DE DE60213615.6T patent/DE60213615T3/de not_active Expired - Lifetime
- 2002-08-20 RS YU13304A patent/RS51699B/sr unknown
- 2002-08-20 AU AU2002325199A patent/AU2002325199B2/en not_active Ceased
- 2002-08-20 NZ NZ547224A patent/NZ547224A/en not_active IP Right Cessation
- 2002-08-20 MX MXPA04001467A patent/MXPA04001467A/es active IP Right Grant
- 2002-08-20 KR KR1020097013183A patent/KR101057488B1/ko not_active Expired - Fee Related
- 2002-08-20 EP EP17194894.6A patent/EP3299029A1/en not_active Withdrawn
- 2002-08-20 JP JP2003520770A patent/JP2004538332A/ja active Pending
- 2002-08-20 HR HRP20120283AA patent/HRP20120283A2/hr not_active Application Discontinuation
- 2002-08-20 PL PL369099A patent/PL215125B1/pl unknown
- 2002-08-20 EP EP02758181.8A patent/EP1420815B2/en not_active Expired - Lifetime
- 2002-08-20 IL IL15996402A patent/IL159964A0/xx unknown
- 2002-08-20 NZ NZ530940A patent/NZ530940A/en unknown
- 2002-08-20 EA EA200400332A patent/EA007533B1/ru not_active IP Right Cessation
- 2002-08-20 PT PT02758181T patent/PT1420815E/pt unknown
- 2002-08-20 AT AT02758181T patent/ATE334698T1/de active
- 2002-08-20 CN CN200910204496.3A patent/CN101675992B/zh not_active Expired - Fee Related
- 2002-08-20 AR ARP020103113A patent/AR036270A1/es active IP Right Grant
- 2002-08-20 EA EA200600974A patent/EA011610B1/ru not_active IP Right Cessation
2004
- 2004-01-29 IS IS7133A patent/IS7133A/is unknown
- 2004-02-20 US US10/783,317 patent/US20050163744A1/en not_active Abandoned
- 2004-02-23 CO CO04015504A patent/CO5560581A2/es not_active Application Discontinuation
2006
- 2006-10-26 CY CY20061101544T patent/CY1105737T1/el unknown
2007
- 2007-12-18 AU AU2007249087A patent/AU2007249087B2/en not_active Expired - Fee Related
- 2007-12-31 IL IL188506A patent/IL188506A/en not_active IP Right Cessation
2008
- 2008-12-19 US US12/339,841 patent/US8871212B2/en not_active Expired - Fee Related
2009
- 2009-06-12 JP JP2009141187A patent/JP5114455B2/ja not_active Expired - Fee Related
2010
- 2010-08-16 AU AU2010212381A patent/AU2010212381B2/en not_active Ceased

Also Published As

Publication number	Publication date
JP2004538332A (ja)	2004-12-24
HUP0400669A2 (hu)	2005-01-28
CO5560581A2 (es)	2005-09-30
AU2010212381B2 (en)	2012-01-19
DK1420815T3 (da)	2006-12-04
EP3299029A1 (en)	2018-03-28
WO2003015812A2 (en)	2003-02-27
CN101675992B (zh)	2014-05-21
EA007533B1 (ru)	2006-10-27
PL369099A1 (pl)	2005-04-18
SI1420815T1 (sl)	2006-12-31
US20100047262A1 (en)	2010-02-25
YU13304A (sh)	2006-08-17
JP2009280582A (ja)	2009-12-03
RS51699B (sr)	2011-10-31
KR20090074830A (ko)	2009-07-07
ES2269749T5 (es)	2017-12-04
US20030157117A1 (en)	2003-08-21
KR20100086520A (ko)	2010-07-30
EA200400332A1 (ru)	2004-08-26
US20050163744A1 (en)	2005-07-28
HK1064934A1 (en)	2005-02-08
AU2002325199B2 (en)	2007-09-20
BR0212047A (pt)	2004-08-17
AR036270A1 (es)	2004-08-25
DE60213615T3 (de)	2017-11-23
AU2007249087A1 (en)	2008-01-10
CA2457140C (en)	2014-08-05
US8871212B2 (en)	2014-10-28
IL188506A (en)	2017-08-31
PT1420815E (pt)	2006-12-29
DE60213615T2 (de)	2007-08-09
EP1420815A2 (en)	2004-05-26
AU2007249087B2 (en)	2010-05-20
CN101675992A (zh)	2010-03-24
PL215125B1 (pl)	2013-10-31
IS7133A (is)	2004-01-29
ES2269749T3 (es)	2007-04-01
IL188506A0 (en)	2008-04-13
KR20040044465A (ko)	2004-05-28
EA011610B1 (ru)	2009-04-28
IL159964A0 (en)	2004-06-20
JP5114455B2 (ja)	2013-01-09
EA200600974A1 (ru)	2006-10-27
HRP20120283A2 (hr)	2012-06-30
NZ547224A (en)	2008-06-30
HUP0400669A3 (en)	2011-07-28
CY1105737T1 (el)	2010-12-22
MXPA04001467A (es)	2005-02-17
EP1420815B2 (en)	2017-08-09
ATE334698T1 (de)	2006-08-15
DE60213615D1 (de)	2006-09-14
AU2010212381A1 (en)	2010-09-09
MY144532A (en)	2011-09-30
CA2457140A1 (en)	2004-02-27
NZ530940A (en)	2007-11-30
EP1420815B1 (en)	2006-08-02
HRP20040218A2 (en)	2004-08-31
KR101057488B1 (ko)	2011-08-19
WO2003015812A3 (en)	2004-03-25
EP1685847A1 (en)	2006-08-02

Publication	Publication Date	Title
MEP43208A (bs)	2011-02-10	Epitopna vakcina beta-amiloidne-analogne-t-ćelije
MEP30408A (en)	2010-10-10	Novel method for down-regulation of amyloid
MXPA02007796A (es)	2003-12-08	Metodo novedoso para la disminucion de cuerpos amiloides.
AR032597A1 (es)	2003-11-19	Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
AU2018298422A1 (en)	2019-12-19	Novel nucleic acid molecules
UA130113C2 (uk)	2025-11-19	Мутеїн інтерлейкіну-21
BR112022016550A2 (pt)	2022-11-16	Proteínas de ligação a flt3 e métodos de uso
BR9907691A (pt)	2000-11-14	Derivados de antìgeno associado a tumor da famìlia mage, e sequências de ácido nucléico codificando os mesmos, usados para a preparação de proteìnas de fusão e de composições para vacinação
NO20023829D0 (no)	2002-08-13	Proteosom influensavaksine
NO20054608L (no)	2005-12-07	Influensavirusvaksine
SE0202110D0 (sv)	2002-07-05	Iscom preparation and use thereof
MY129263A (en)	2007-03-30	Vaccine composition
MX2022013963A (es)	2023-02-22	Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
AR023535A1 (es)	2002-09-04	Nuevas composiciones.
BR0211761A (pt)	2007-01-09	depsipeptìdeos e processos para preparar os mesmos
WO2005012330A3 (en)	2005-09-09	AMYLOID β-PEPTIDE AND METHODS OF USE
EA200801411A1 (ru)	2008-10-30	Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
EA202191735A1 (ru)	2021-11-24	Варианты альфа-галактозидазы человека
SE9903534D0 (sv)	1999-09-30	Vaccin
DE60126490D1 (de)	2007-03-22	Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
AR248047A1 (es)	1995-05-31	Procedimiento para la preparacion de una vacuna a base de virus del herpes bovina modificado tipo 1.
AR027738A1 (es)	2003-04-09	Composicion coadyuvante, composiciones de vacunas que incluyen dicha composicion coadyuvante; procedimiento de induccion de inmunorespuestas antigenicas enmamiferos y procedimiento de tratamiento donde se aplican dichas vacunas
YU87201A (sh)	2004-09-03	Postupak za nishodnu regulaciju gdf-8 aktivnosti
CU23009A1 (es)	2004-12-17	Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos